[go: up one dir, main page]

DK2854769T3 - Fremgangsmåder til behandling af artritis - Google Patents

Fremgangsmåder til behandling af artritis Download PDF

Info

Publication number
DK2854769T3
DK2854769T3 DK13813286.5T DK13813286T DK2854769T3 DK 2854769 T3 DK2854769 T3 DK 2854769T3 DK 13813286 T DK13813286 T DK 13813286T DK 2854769 T3 DK2854769 T3 DK 2854769T3
Authority
DK
Denmark
Prior art keywords
arthritis
treatment
methods
Prior art date
Application number
DK13813286.5T
Other languages
English (en)
Inventor
Keelung Hong
Luke S S Guo
Yun-Long Tseng
Sheue-Fang Shih
Po-Chun Chang
Chih-Chiang Tsai
hong-hui Lin
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Application granted granted Critical
Publication of DK2854769T3 publication Critical patent/DK2854769T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK13813286.5T 2012-07-05 2013-07-05 Fremgangsmåder til behandling af artritis DK2854769T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668446P 2012-07-05 2012-07-05
US201361791650P 2013-03-15 2013-03-15
PCT/US2013/049442 WO2014008469A2 (en) 2012-07-05 2013-07-05 Methods of treating arthritis

Publications (1)

Publication Number Publication Date
DK2854769T3 true DK2854769T3 (da) 2023-06-26

Family

ID=49882628

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13813286.5T DK2854769T3 (da) 2012-07-05 2013-07-05 Fremgangsmåder til behandling af artritis

Country Status (24)

Country Link
US (5) US9789062B2 (da)
EP (1) EP2854769B1 (da)
JP (2) JP6535281B2 (da)
KR (2) KR102176971B1 (da)
CN (1) CN105377238B (da)
AU (1) AU2013286575B2 (da)
BR (1) BR112015000174A2 (da)
CA (1) CA2878152C (da)
CY (1) CY1126136T1 (da)
DK (1) DK2854769T3 (da)
ES (1) ES2949093T3 (da)
FI (1) FI2854769T3 (da)
HR (1) HRP20230655T1 (da)
HU (1) HUE062466T2 (da)
LT (1) LT2854769T (da)
NZ (1) NZ703532A (da)
PL (1) PL2854769T3 (da)
PT (1) PT2854769T (da)
RU (1) RU2677658C2 (da)
SG (2) SG10201610887WA (da)
SI (1) SI2854769T1 (da)
TW (1) TWI556838B (da)
WO (1) WO2014008469A2 (da)
ZA (1) ZA201500152B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
WO2017203529A1 (en) * 2016-05-24 2017-11-30 Bol Pharma Ltd. Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
US20190262363A1 (en) * 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN107670020B (zh) * 2016-08-02 2020-09-18 富比积生物科技股份有限公司 四胜肽gekg在治疗退化性关节炎中的用途
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
RU2667467C1 (ru) * 2017-05-17 2018-09-19 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Липосомальный препарат дексаметазона в гипертоническом растворе хлорида натрия и способ лечения острого повреждения легких на его основе
CN111093623A (zh) * 2017-07-10 2020-05-01 免疫疫苗技术公司 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途
CA3219776A1 (en) * 2017-08-22 2019-02-28 Moebius Medical Ltd. Liposomal formulation for joint lubrication
US20200353062A1 (en) * 2017-11-09 2020-11-12 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
US12083138B2 (en) * 2018-07-09 2024-09-10 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
WO2020056399A1 (en) * 2018-09-16 2020-03-19 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
WO2020102323A1 (en) * 2018-11-14 2020-05-22 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof
CA3187955A1 (en) * 2020-08-05 2022-02-10 Sheue-Fang Shih Pharmaceutical composition of intra-articular corticosteroid for pain control
US11896713B2 (en) * 2020-10-22 2024-02-13 Rutgers, The State University Of New Jersey Strategies to enhance lung cancer treatment
CN112791063A (zh) * 2021-01-19 2021-05-14 南通市中医院 一种用于清除关节腔积液中炎症因子及释放抗炎药物的载体
RU2762105C1 (ru) * 2021-05-25 2021-12-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ оценки эффективности лечения псориатического артрита с помощью параметров антиоксидантной системы
US20230098714A1 (en) * 2021-08-06 2023-03-30 New York R&D Center For Translational Medicine And Therapeutics, Inc. Microrna compositions and methods of use
US20250177333A1 (en) * 2022-03-08 2025-06-05 Nova Southeastern University Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10)
EP4654956A1 (en) * 2023-01-26 2025-12-03 Insignia Pharmaceuticals, LLC Pharmaceutical compositions for treating osteoarthritis
KR20250018222A (ko) * 2023-07-26 2025-02-05 차의과학대학교 산학협력단 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201010A (en) * 1981-06-19 1986-02-21 Ciba Geigy Ag The treatment of inflammation diseases using desferrioxamine
MX9203290A (es) * 1983-09-19 1992-08-01 Liposome Co Inc Suministro localizado usando conjugados de fibronectina.
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5846217A (en) * 1997-07-29 1998-12-08 Iomed, Inc. Iontophoretic bioelectrode and method of using same
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
GB0118517D0 (en) 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
EP1371362A1 (en) 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
JP4790597B2 (ja) * 2003-04-24 2011-10-12 ヤゴテック アーゲー 規定されたコア幾何学的配置を有する遅延放出錠
ES2641570T3 (es) 2004-03-31 2017-11-10 University Of Utah Research Foundation Sistemas de suministro macromoleculares para imagenología no invasiva, evaluación y tratamiento de artritis y otras enfermedades inflamatorias
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
JP5355890B2 (ja) * 2004-09-09 2013-11-27 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム グルココルチコイドおよびグルココルチコイド誘導体のリポソーム性組成物
JP5571308B2 (ja) 2005-09-15 2014-08-13 マリーナ バイオテック,インコーポレイテッド 両性リポソームにおけるまたはそれに関する改善
ES2895078T3 (es) * 2006-03-15 2022-02-17 Brigham & Womens Hospital Inc Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
ATE472998T1 (de) 2006-05-18 2010-07-15 Medigene Ag Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
CN101512828B (zh) 2006-07-06 2011-05-11 夏普株式会社 染料敏化型太阳能电池组件及其制备方法
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
EP2086507B1 (en) 2006-10-06 2018-11-07 BioNet Pharma GmbH A spinal nucleus pulposus implant
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
CA2800693A1 (en) 2010-05-28 2011-12-01 Purdue Research Foundation Delivery of therapeutic agents to inflamed tissues using folate-targeted agents
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂

Also Published As

Publication number Publication date
JP6964571B2 (ja) 2021-11-10
EP2854769B1 (en) 2023-06-07
AU2013286575A1 (en) 2015-02-26
SG11201408810TA (en) 2015-01-29
CA2878152A1 (en) 2014-01-09
HK1219414A1 (zh) 2017-04-07
CN105377238B (zh) 2018-09-07
PL2854769T3 (pl) 2023-08-07
US11793755B2 (en) 2023-10-24
KR102176971B1 (ko) 2020-11-11
EP2854769A4 (en) 2015-12-09
HRP20230655T1 (hr) 2023-10-13
AU2013286575B2 (en) 2017-11-02
CN105377238A (zh) 2016-03-02
US20210145744A1 (en) 2021-05-20
FI2854769T3 (fi) 2023-06-22
US10322086B2 (en) 2019-06-18
CA2878152C (en) 2020-12-29
SI2854769T1 (sl) 2023-09-29
ZA201500152B (en) 2020-05-27
US20170367979A1 (en) 2017-12-28
TW201406404A (zh) 2014-02-16
HUE062466T2 (hu) 2023-11-28
KR20200096667A (ko) 2020-08-12
US20150174069A1 (en) 2015-06-25
ES2949093T3 (es) 2023-09-25
JP6535281B2 (ja) 2019-06-26
EP2854769A2 (en) 2015-04-08
US9789062B2 (en) 2017-10-17
RU2015103538A (ru) 2016-08-20
NZ703532A (en) 2018-02-23
BR112015000174A2 (pt) 2017-06-27
US10959951B2 (en) 2021-03-30
JP2019069962A (ja) 2019-05-09
US10736846B2 (en) 2020-08-11
WO2014008469A2 (en) 2014-01-09
US20190290583A1 (en) 2019-09-26
AU2013286575A2 (en) 2015-03-12
LT2854769T (lt) 2023-07-10
KR102302503B1 (ko) 2021-09-15
KR20150048710A (ko) 2015-05-07
JP2015522041A (ja) 2015-08-03
RU2677658C2 (ru) 2019-01-18
US20200276123A1 (en) 2020-09-03
PT2854769T (pt) 2023-07-05
CY1126136T1 (el) 2023-11-15
TWI556838B (zh) 2016-11-11
SG10201610887WA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
DK2854769T3 (da) Fremgangsmåder til behandling af artritis
LT2885010T (lt) Tautopatijos gydymo būdai
DK2968208T3 (da) Behandling af kataplexi
DK2717941T3 (da) Behandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
DK2785349T4 (da) Kombinationsbehandling af cancer
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK3021838T3 (da) Behandling af fedme
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK2970775T3 (da) Produktion af aromater ud af di- og poly-oxygenater
DK2976359T3 (da) Fremgangsmåder til behandling af osteogenesis imperfecta
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
DK2563385T3 (da) Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK2906580T3 (da) Behandling af amyotrofisk lateral sklerose
DK2906219T3 (da) Orvepitant til behandling af kronisk pruritus
DK2807170T3 (da) Phragmalin-limonoider til behandlingen af seksuel dysfunktion
EP2880048A4 (en) METHOD
DK2705847T3 (da) Sammensætning til behandling af psoriasis
LT3202769T (lt) Fosfaplatinos junginių gryninimo būdas
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK2838850T3 (da) Oprensning af titantetrachlorid
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion